In eight mechanically ventilated patients in cardiogenic shock, we assessed the hemodynamic effects of an infusion of dopamine and dobutamine and evaluated its role in preventing the deleterious effects of administering each amine alone. Each patient received three infusions in a randomly assigned order: dopamine, 15 ,.tg/kg/min; dobutamine, 15 ,tg/kg/min; and a combination of dopamine, 7.S ,g/kg/min, and dobutamine, 7.5 ,ug/kg/min. Stroke volume index increased similarly with the three infusions, but dopamine alone increased oxygen consumption (p < 0.05 vs dobutamine alone and dopamine-dobutamine combined). The dopamine-dobutamine combination increased mean arterial pressure (p < 0.05 vs dobutamine), maintained pulmonary capillary wedge pressure within normal limits (p < 0.05 vs dopamine), and prevented the worsening of hypoxemia induced by dopamine (p < 0.05). The dopamine-dobutamine combination appears to be useful in the management of mechanically ventilated patients in cardiogenic shock.
THE HEMODYNAMIC PICTURE of heart failure is characterized by a decrease in stroke volume and an increase in ventricular filling pressures. When acute pump failure is so severe that an adequate cardiac output cannot be maintained, hypotension supervenes despite the elevated peripheral resistance, and cardiogenic shock ensues. In this setting, diuretics and vasodilators cannot be used alone, and the therapeutic use of sympathomimetic amines such as dopamine and dobutamine is required.
Dopamine, a precursor in the endogenous synthesis of norepinephrine, is a potent inotropic agent.I-1 It increases stroke volume both by a direct action and through the release of norepinephrine stores.4 When dopamine is used at a dose of 10-15 ig/kg/min, vasopressor effects appear. These effects are of particular value in patients with hypotension.5 However, an important side effect limits its use in cardiogenic shock: At a dose of 10 to 15 ,ug/kg/min, it may induce an increase in pulmonary capillary wedge pressure (PCWP). As a result, its use may be associated with pulmonary vascular congestion, arterial desaturation and increase in venous admixture. 6 Dobutamine is also a potent inotropic agent that acts directly on adrenergic myocardial receptors without any release of norepinephrine from nerve endings.' In the treatment of severe heart failure, dobutamine induces an increase in cardiac output and stroke volume with a reduction of PCWP.6 In contrast to dopamine, dobutamine probably has minimal direct vascular activity even when it is used at higher dosages. However, a reduction in systemic arterial resistance (SAR), frequently accompanied by a slight fall in mean arterial pressure (MAP), generally occurs during dobutamine infusion in patients with chronic, low-output cardiac failure.8 This decrease in SAR may be due to a reduc-tion in compensatory vasoconstriction secondary to an improvement in stroke volume index (SVI).
The aim of this study was to assess the efficacy of a combined dopamine-dobutamine infusion, 7.5 Ag/kgl min each, in the treatment of cardiogenic shock and in the prevention of the deleterious effects of each sympathomimetic amine used alone.
Methods
We studied eight patients in cardiogenic shock who required continuous mechanical ventilation. Mechanical ventilation was instituted when drug treatment of pulmonary edema with hypotension by diuretics, digitalis glycosides or vasodilators was insufficient or ineffective.
The group consisted of five men and three women, ages 60-75 years (mean 65 years). Before the onset of cardiogenic shock, patients were in congestive heart failure (New York Heart Association class III or IV) controlled by conventional treatment with digitalis, diuretics and vasodilators. The cause of heart failure was coronary artery disease in four patients and idiopathic cardiomyopathy in four. The etiology of ischemic heart disease did not affect the clinical findings. Three patients were in chronic atrial fibrillation. No patient had suffered acute myocardial infarction within the 7 preceding days.
Hemodynamic studies were performed on the second day of assisted ventilation. A constant tidal volume (15 ml/kg) with a I/E of /2 was delivered with a volume-controlled ventilator (Siemens servo ventilator 900 B). Positive end-expiratory pressure (PEEP) was never used.
Two days before the study, arterial and thermistortipped Swan Ganz catheters were inserted. Cardiac output was measured in triplicate by the thermodilution method (Edwards model 9510) after injecting 10 ml of isotonic glucose at 0°C into the right atrium. Right atrial pressure (RAP), mean pulmonary arterial pressure (MPAP), PCWP and MAP were monitored using Bentley-Trantec transducers connected to the arterial and Swan Ganz catheters. Cardiac index (CI), stroke index (SI), left ventricular stroke work index (LVSWI) and SAR were calculated from standard for-mulas. Blood gas tensions in arterial (Pao2 and Paco2) and mixed venous blood (Pvo2 and Pvco2) were determined by standard electrode technique (ABL 1 Radiometer) and corrected for the patient's temperature. An OSM2 radiometer was used to measure hemoglobin and hemoglobin oxygen saturation (SaO2 and SvO2). From these measurements, arterial and mixed venous oxygen contents (CaO2 and CvO2), arteriovenous oxygen content difference (avDO2), venous admixture (Qva/Qt) with a respiratory quotient of 0.8 and oxygen consumption (VO2) were calculated by standard formulas.
Each patient received three infusions in a randomly assigned order: dopamine, 15 I-s C dobutamine, 7.5 ,g/kg/min. All other treatments, such as digitalis glycosides, diuretics and vasodilators, were stopped during the 6-8 hours of the study. Between each infusion, a 1-hour interval was allowed for variables to return to baseline levels. Patients were ventilated (FiO2 = 1) at all times of measurement. PCWP was always measured during the tele-expiratory phase. All measurements were performed 30 minutes after the onset of each infusion. Patients were sedated with diazepam and anesthetized, if necessary, with pancuronium bromide during the study. Body temperature did not change significantly during the study.
Results
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The Pao2 was significantly lower (p < 0.05) during dopamine infusion than during dobutamine and dopamine-dobutamine infusions. Q ia/Qt increased to a similar extent during each of the three infusions. The increase in PvO2 during dobutamine and dopaminedobutamine infusions was smaller than during dopamine infusion (NS) (table 5). V02 was significantly higher (p < 0.05) during dopamine infusion than during dobutamine and dopamine-dobutamine infusions (table 5).
Discussion
All our patients in cardiogenic shock received intermittent positive pressure ventilation (IPPV) without PEEP. Mechanical ventilation was instituted when drug treatment of pulmonary edema with hypotension proved ineffective with diuretics, digitalis glycosides, vasodilators and dobutamine. Under these circumstances we measured tele-expiratory PCWP and believe that this measurement gave a good estimation of transmural pressures. This was assumed because during the passive expiratory phase of IPPV, intrathoracic pressure (i.e., intrapleural or intraesophageal pressure) is near atmospheric pressure, since passive expiration in sedated patients is only affected by the elastic recoil pressure of the lung. This estimation was considered to be accurate, as PEEP was not used and sympathomimetic amines have no known effects on chest wall and lung compliance. Mechanical ventilation can induce a decrease in tele-expiratory PCWP by increasing intrathoracic pressure and reducing venous return.9 An increase in intrathoracic pressure is also associated with a decrease in cardiac output and in systemic arterial pressure.'0
Our results clearly indicate that an improvement in hemodynamic status occurs during infusion of the dopamine and dobutamine, 7.5 ug/kg/min each. MAP, CI and SVI increase, while PCWP remains normal. No severe hypoxemia and no dramatic change in SAR appear. To our knowledge, these findings have not been previously reported.
The three infusions have a similar effect on cardiac output, but this effect is associated with a higher V02 with dopamine infusion than with dopamine-dobutamine combined. Moreover, in two of our patients in cardiogenic shock, the capacity of dopamine alone to improve cardiac output was reduced. This reduced and often unpredictable effect of dopamine in patients in heart failure has been reported previously."' 12 The cause is a depletion of endogenous noradrenaline stores rather than an increase in SAR."' 12 The hemodynamic effects of dopamine decrease after 72 hours of infusion, and a transient cardiocirculatory deterioration could appear after withdrawal of dopamine. I3 The association of dobutamine, a potent inotropic agent that acts directly on myocardial /3, adrenergic recep-623 VOL 67, No 3, MARCH 1983 tors, can prevent this deleterious effect. Our results indicate a similar increase in venous admixture after the three treatments. An increase in Qva/Qt is the consequence of improvement in cardiac output. When car-diac output increases, a recruitment mechanism is observed with opening of capillaries in unventilated areas of the lung.'4 However, dopamine increases hypoxemia, probably as a consequence of increasing PCWP Comparison between the three treatments using A (30-0) index and two-way analysis of variance. Abbreviations: CI = cardiac index; SI = stroke index; LVSWI = left ventricular stroke work index; HR = heart rate. and lack of augmentation in Po2. An increase in venous tone and in V02 with dopamine explains these deleterious effects. '4 In our patients, a similar effect on cardiac output is obtained with dopamine-dobutamine and with dobutamine; but dobutamine does not improve MAP and slightly reduces SAR. Failure to increase MAP is a common feature of dobutamine in severe congestive heart failure. '5 16 The decrease in SAR is due more to the improvement in cardiac output than to the effect of dobutamine on peripheral ,82-adrenergic receptors. As the a-and ,B-adrenergic effects of dobutamine are balanced, there is no change in peripheral vascular tone, and the slight reduction in SAR may be due to the disappearance of the compensatory vasoconstriction that occurs in heart failure.17 All of these hemodynamic effects explain the superiority of dobutamine over dopamine in chronic heart failure without hypotension.6' 8 In patients in cardiogenic shock, restoration of arterial pressure evidently improves coronary and systemic perfusion. In our patients, an increase in arterial pressure was one of the most important goals because of the hemodynamic effects of mechanically controlled ventilation. In this situation our results clearly indicate that a combination of dopamine and dobutamine, 7.5 ,ug/kg/min each, induces a slight improvement in arterial pressure without increasing PCWP.
Comparison of dopamine and dopamine-dobutamine vs dobutamine using

Comparison of dopamine vs dobutamine and vs dopamine-dobutamine using
During the control period, tele-expiratory PCWP measurements appeared slightly low for patients with heart failure, as a result of the effects of mechanical ventilation.9 With mechanical ventilation, as with potent vasodilator therapy, the maintenance of optimal preload is of dramatic importance to gain maximal benefit through the Frank-Starling mechanism. PCWP may decrease with dobutamine infusion. This effect is of particular importance in reducing pulmonary edema and hypoxemia in nonventilated patients. Thus, in our ventilated patients, a decrease in end-expiratory PCWP is due to dobutamine, but also to mechanical ventilation. In patients with heart failure, an average PCWP of 15-20 mm Hg maintains the best inotropic effect.'-2' Below this level, myocardial inefficiency may occur. 20 The association of mechanical ventilation and dobutamine can induce this theoretical side effect. A dopamine-dobutamine combination prevents this slight reduction in PCWP. An increase in venous tone with dopamine, associated with an increase in CI rather than a blood volume expansion, compensates more consistently for this fall in PCWP.
A disadvantage with dobutamine used alone is that it does not cause selective renal and mesenteric vasodilatation, as does dopamine. 22 The lower dosage of dopamine rendered possible by the combination of dopamine and dobutamine induces an increase in renal blood flow, glomerular filtration rate, urine flow and sodium excretion,2 23 which is of dramatic importance in patients with severe heart failure. This preferential action of dopamine is a result of direct renal vasodilatation by stimulation of renal dopaminergic receptors and is of particular value during mechanical ventilation, which tends to reduce glomerular filtration and to increase sodium retention. 24 
